NGS

Global Genomics Market Research Report 2021: Focus on Functional Genomics & Pathway Analysis - Forecast to 2028 - ResearchAndMarkets.com

Thursday, October 14, 2021 - 4:25pm

The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has also led to an increase in the market competition, coupled with the development of breakthrough genomic technologies by Veritas Genetics, 23andMe, and other key players.
  • In August 2020, Ancestry launched a new next-generation sequencing-based tool to screen genes linked to blood disorders, colon cancer, heart diseases, and breast cancer.
  • This product, developed by Quest Diagnostics, has a better DNA analysis efficiency when compared to microarray-based testing.

Global Oncology Molecular Diagnostics Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Thursday, October 14, 2021 - 2:19pm

Oncology molecular diagnostics help perform rapid analysis and provide detailed information that is further utilized in the personalized treatment of cancer.

Key Points: 
  • Oncology molecular diagnostics help perform rapid analysis and provide detailed information that is further utilized in the personalized treatment of cancer.
  • How has the global oncology molecular diagnostics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology molecular diagnostics market?
  • What is the structure of the global oncology molecular diagnostics market and who are the key players?

Clear Labs Automated NGS Technology Platform (Clear Safety™) Approved by USDA's National Poultry Improvement Plan for Salmonella Detection

Thursday, October 14, 2021 - 2:00pm

SAN CARLOS, Calif., Oct. 14, 2021 /PRNewswire-PRWeb/ -- Today, Clear Labs , a leader in providing fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, is announcing that Clear Safety Salmonella has been approved by the National Poultry Improvement Plan (NPIP) for interim use in the detection of Salmonella.

Key Points: 
  • SAN CARLOS, Calif., Oct. 14, 2021 /PRNewswire-PRWeb/ -- Today, Clear Labs , a leader in providing fully automated, next-generation sequencing (NGS) platforms for turnkey diagnostics, is announcing that Clear Safety Salmonella has been approved by the National Poultry Improvement Plan (NPIP) for interim use in the detection of Salmonella.
  • "The approval from NPIP is a big validation for the power and promise of our platform that focuses on timely detection providing deeper insights.
  • Clear Labs is widely recognized as a pioneer in fully automated NGS-based food safety for Salmonella and Listeria detection.
  • Clear Labs helps companies gain greater operational awareness and leverages its turnkey NGS food safety testing platform to protect brands and ensure consumer safety.

Study Shows the Combination of OGM and NGS with Linked-Reads Detects Significantly More Clinically Relevant Variants Resulting in Higher Success Rates for Resolving Previously Unclassified Subjects in Genetic Disease Research

Thursday, October 14, 2021 - 1:00pm

The authors also identified candidate variants in another 60% (18 of 30 cases) for future follow-up.

Key Points: 
  • The authors also identified candidate variants in another 60% (18 of 30 cases) for future follow-up.
  • FGA provides information beyond current assays and results in higher resolution genome maps that can be used for future studies.
  • Fifty percent of the participants in this study had clinically relevant variants hidden in their genomes that WES alone had not uncovered.
  • We believe there is tremendous potential in using OGM together with NGS to understand disease from the very beginning of any study.

OpGen Announces $15 Million Registered Direct Offering

Thursday, October 14, 2021 - 1:00pm

The gross proceeds from the offering are expected to be approximately $15 million before deducting placement agent fees and other offering expenses.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $15 million before deducting placement agent fees and other offering expenses.
  • The securities described above are being offered and sold by OpGen in a registered direct offering pursuant to a shelf registration statement on Form S-3 (Registration No.
  • A final prospectus supplement and base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SECs website located at http://www.sec.gov.
  • This press release includes statements regarding the Companys registered direct offering and the use of proceeds therefrom.

Global $3.2B Microbiome Sequencing Services Market 2021-2027 - Shotgun Metagenomic Sequencing Technology Anticipated to Witness the Highest Growth - ResearchAndMarkets.com

Thursday, October 14, 2021 - 12:16pm

The "Global Microbiome Sequencing Services Market (2021-2027) by Technology, Application, Research Type, Laboratory Type, End-users, and Geography: Impact of COVID-19, Ansoff Analysis, Competitive Quadrant" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Microbiome Sequencing Services Market (2021-2027) by Technology, Application, Research Type, Laboratory Type, End-users, and Geography: Impact of COVID-19, Ansoff Analysis, Competitive Quadrant" report has been added to ResearchAndMarkets.com's offering.
  • Effective understanding and application of microbiome sequencing services would help in the commercialization of personalized medicine and diet.
  • Due to advancements in technology, there has been a rise in the NGS (Next-Gen Sequencing) to generate microbiome data.
  • By Technology, Shotgun Metagenomic Sequencing Technology is anticipated to witness the largest growth in the microbiome sequencing market.

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

Thursday, October 14, 2021 - 1:00pm

Pillar Biosciences , an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp (NYSE: LH), a leading global life sciences company, to provide genomic testing for people with cancer.

Key Points: 
  • Pillar Biosciences , an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics company, today announced that it has entered into an agreement with Labcorp (NYSE: LH), a leading global life sciences company, to provide genomic testing for people with cancer.
  • Under the agreement, Pillar Biosciences will provide the oncoReveal Essential Myeloproliferative Neoplasm (MPN) panel.
  • Collaborating with Labcorp makes available a targeted NGS testing solution to accurately diagnose and monitor people with cancer who are suspected of having myeloproliferative neoplasms, which are diseases of the blood and bone marrow, said Laura Beggrow, Chief Business Officer at Pillar Biosciences.
  • "This collaboration presents a broad market opportunity and bolsters our mission to make precision medicine accessible to all by providing high-quality, affordable specialty NGS testing capabilities.

A.I.S. Resources Gravity Geophysics Reveals Highly Prospective New Gold Drill Targets at Fosterville Toolleen Gold Project

Thursday, October 14, 2021 - 8:31am

Resources Limited ( TSX: AIS, OTCQB: AISSF ) (the Company or AIS) announces it has received the Geophysics Reprocessing Report from Nordic Geoscience.

Key Points: 
  • Resources Limited ( TSX: AIS, OTCQB: AISSF ) (the Company or AIS) announces it has received the Geophysics Reprocessing Report from Nordic Geoscience.
  • The red circles in figure one below show the major drill targets on R1 and R2 on the second order faults resulting from the analysis.
  • The latest techniques using NGS (Next Gen Sequencing) Enhanced Ground Gravity processing, Gravity Grid enhancements and Gravity Multi-Scale Edge detection were used to refine locations of mineralization.
  • It also has joint venture interests with Spey Resources Corp in lithium brines in Argentina at Incahuasi and Pocitos salars.

Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research

Wednesday, October 13, 2021 - 1:00pm

Twist will market this expert-developed exome panel as the Twist Alliance Clinical Research Exome .

Key Points: 
  • Twist will market this expert-developed exome panel as the Twist Alliance Clinical Research Exome .
  • The Twist Alliance Clinical Research Exome helps support the Broad Institute Genomics Platform and was designed using validated data from clinical patient samples.
  • Exome sequencing has long been a key part of our sequencing efforts for large cancer and germline research studies.
  • Well designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing.

SOPHiA GENETICS offers new genomic application for a deeper investigation of Mendelian diseases

Tuesday, October 12, 2021 - 8:36pm

BOSTON and LAUSANNE, Switzerland, Oct. 12, 2021 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of SOPHiA Clinical Exome Solution v3, a new genomic application that offers enhanced probe design and increased detection capabilities for a deeper investigation of Mendelian diseases.

Key Points: 
  • The SOPHiA DDM platform analyzes complex NGS data by detecting, annotating, and pre-classifying multiple types of genomic variants in all the genes of the panel.
  • To learn more about the SOPHiA Clinical Exome Solution v3 application, visit https://www.sophiagenetics.com/clinical/inherited-disorders/rare-disease... .
  • SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research.
  • SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise.